Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: Three-year results of the XAMI trial

EuroIntervention

Volumn 10, Issue 11, 2015, Pages 1280-1283

  Hofma, Sjoerd H ^a   Smits, Pieter C ^b   Brouwer, Jan ^a   Velders, Matthijs A ^a   Van 't Hof, Arnoud W J ^c   Queré, Michel ^a   De Vries, Cornelis Jan ^a   Van Boven, Adrianus J ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b Maasstad Hospital   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

Author keywords

Drug eluting stent; Primary PCI; STEMI

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; RAPAMYCIN; ANTINEOPLASTIC AGENT;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FOLLOW UP; HEART DEATH; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIROLIMUS ELUTING STENT; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; AGED; COMPARATIVE STUDY; DEVICES; FEMALE; HEART MUSCLE REVASCULARIZATION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REOPERATION; UTILIZATION;

AGED; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PERCUTANEOUS CORONARY INTERVENTION; REOPERATION; SIROLIMUS;

EID: 84927653608     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJY15M01_03     Document Type: Article

References (6)

1. Hofma SH, Brouwer J, Velders MA, van 't Hof AW, Smits PC, Queré M, de Vries CJ, van Boven AJ. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2012;60:381-7.
2. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Chiu Wong S, Fahy M, Parise H, Mehran R; HORIZONSAMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-204.
3. Räber L, Kelbæk H, Ostojic M, Baumbach A, Heg D, Tüller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Lüscher TF, Taniwaki M, Matter CM, Meier B, Jüni P, Windecker S; COMFORTABLE AMI Trial Investigators. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012;308:777-87.
4. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW. Clinical outcomes with drug-eluting and bare metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62:496-504.
5. Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, de Luca G. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial. JACC Cardiovasc Interv. 2014;7:849-56.
6. Sarno G, Lagerqvist B, Nilsson J, Frobert O, Hambraeus K, Varenhorst C, Jensen UJ, Tödt T, Götberg M, James SK. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol. 2014;64:16-24.